Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

NLNK $14.99 1.6700 +12.54%
DRNA $4.74 0.4300 +9.98%
ZIOP $5.91 0.4300 +7.85%
ATRA $21.81 1.0000 +4.81%
ARGS $4.69 0.2100 +4.69%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

EXEL $13.35 -2.1300 -13.76%
NWBO $0.57 -0.0493 -7.92%
SPHS $3.08 -0.2200 -6.67%
JUNO $31.30 -2.1200 -6.34%
KITE $56.46 -3.5800 -5.96%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

June 30 Deadline to Report Electronic Prescriptions to Avoid 2014 Payment Adjustment

(ASTRO) June 3, 2013 - Eligible professionals must successfully report as electronic prescribers by June 30, 2013, to avoid Medicare Part B payment adjustments in 2014. Although the program does not apply to many radiation oncologists, ASTRO urges all radiation oncologists to review the program criteria to confirm their status.
read article 



The Sunshine Act — Effects on Physicians

(NEJM) May 30, 2013 - The new Physician Payments Sunshine Act requires public reporting of payments to physicians and teaching hospitals from pharmaceutical and medical device companies, as well as reporting of certain ownership interests (see box).
read article 



Oncology Practices to Lose $250K Annually to Budget Sequester

(BizJournals.com) June 5, 2013 - The budget sequester that went into effect in March reduced Medicare reimbursement for oncology drugs from 6 percent (plus the average sales price) to 4 percent. This move will cost the average independent community oncology practice $250,000 each year, according to global sales and marketing firm ZS Associates
read article 



Verastem Appoints Robert Forrester as Chief Executive Officer

(Daily Finance) June 6, 2013 - Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that Robert Forrester, President and Chief Operating Officer, will be named President, Chief Executive Officer and a Director, and that Christoph Westphal, M.D., Ph.D., Chairman and Chief Executive Officer, will be transitioning to Executive Chairman.
read article 



Regional Cancer Care Associates (RCCA) and GenPath Oncology Announce Diagnostic Laboratory Partnership to Benefit Nearly a Quarter Million NJ Cancer Patients

(Yahoo! Finance) June 5, 2013 - Regional Cancer Care Associates LLC (RCCA), one of the nation's largest oncology physician groups, announced today it has partnered with GenPath Oncology (www.genpath.com), a business unit of BioReference Laboratories to bring advanced diagnostics to the practice's more than 230,000 cancer patients.
read article 



Roswell Park Cancer Institute, Jasco Pharmaceuticals Join Forces to Advance Drug Research

(Wall Street Journal) May 31, 2013 - A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute (RPCI) and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacological therapy that shows promise for treating both solid-tumor cancers and hematologic malignancies.
read article (paid subscription required) 



Isis Execs Upbeat as AstraZeneca Expands Cancer Drug Collaboration

(Xconomy San Diego) June 5, 2013 - Executives at Carlsbad-based Isis Pharmaceuticals were upbeat in a conference call this week, after the company reported encouraging news on several fronts.
read article 



Targovax AS Raises $3.6 Million in Private and Public Support for TG01 Pancreatic Cancer Vaccine Development

(Yahoo! Finance) June 5, 2013 - Cancer vaccine specialist Targovax today announced that it has raised a total of $3.6 million to accelerate development of its RAS mutation-targeted therapeutic cancer vaccine pipeline, specifically lead candidate TG01 for pancreatic cancer.
read article 



Lofty Expectations Hit BioMarin in Development of New Cancer Drugs

(MarketWatch/Health Exchange blog) June 3, 2013 - While Merck & Co. Inc. and others are impressing Wall Street and investors with their cancer-fighting drugs, BioMarin Pharmaceuticals is finding that expectations are growing lofty —and failure to meet them could prove hazardous to your stock price.
read article 



Infinity Pharmaceuticals Tries to Regain Footing after a Rough Session

(MarketWatch/Health Exchange blog) June 4, 2013 - After falling off a precipice Monday, shares of Infinity Pharmaceuticals tried to rebound on Tuesday and gained more than 20% to around the $20 level.
read article 



Tackling Cancer: Your Best Investing Ideas

(Motley Fool) June 1, 2013 - Over the past three months, we've taken a deep dive into the 12 cancer types most likely to be diagnosed in the U.S. this year according to the American Cancer Society (link opens PDF file).
read article 



AVEO Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma

(MarketWatch) June 10, 2013 - AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) informing the company that the FDA will not approve in its present form the New Drug Application (NDA) for AVEO’s investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma (RCC).
read article 



47% of Britons Will Develop Cancer in Their Lifetime by 2020, Study Shows

(The Guardian UK) June 7, 2013 - Rates of cancer are rising so much that by 2020 almost half of Britons will develop the disease in their lifetime, but more people will survive the country's biggest killer, a new analysis reveals.
read article 



Letters: The Continuing Debate Over Health Costs

(New York Times) June 6, 2013 - To the Editor: “The $2.7 Trillion Medical Bill” (“Paying Till It Hurts” series, front page, June 2) effectively highlights the wide price variations for medical care in the United States and the role they play in the ballooning cost of care.
read article 



Biotech Stock Mailbag: 2013 Clinical Trials Calendar

(TheStreet) June 7, 2013 - I'm just back from covering the American Society of Clinical Oncology (ASCO) annual meeting -- and still recovering -- so apologies in advance for a less-full Biotech Stock Mailbag this week.
read article 



Regeneron Shares Soar on New Testing for Eye Medicine

(MarketWatch/Health Exchange blog) June 6, 2013 - Regeneron Pharmaceuticals got a jolt in the markets Thursday as the drug maker’s Eylea medicine got another dose of good news, proving effective in treating a degenerative eye disease.
read article 



Judge's Ruling Challenges US Transplant System

(New York Times/Associated Press) June 7, 2013 - It's a life or death matter: Who gets the next scarce donated organ? In an unprecedented challenge to the nation's transplant system, a federal judge has allowed one dying child — and a day later another — to essentially jump the line in rulings that could have ramifications for thousands of people awaiting new organs.
read article 



Is Big Pharma Learning From Its Late Stage R&D Setbacks?

(Forbes) June 7, 2013 - Big Pharma hardly needs to be warned of the fickle nature of drug development, but the industry received a timely reminder on Monday when Sanofi announced the termination of two late-stage assets; iniparinib for lung cancer and otamixaban for acute coronary syndromes.
read article 



Glaxo's Avandia Scores FDA Victory

(Wall Street Journal) June 7, 2013 - A government panel called for easing restrictions on diabetes drug Avandia, in a remarkable about-face nearly three years after concerns over heart risk led regulators to curtail use of the drug.
read article (paid subscription required) 



The Neanderthal With the World's Oldest Tumor

(National Geographic Daily News) June 5, 2013 - A benign bone tumor that afflicts modern-day humans has now been found in one of our ancestors: a Neanderthal more than 120,000 years old.
read article 



Living With Cancer: Look Good, Feel Better

(New York Times/Well blog) June 6, 2013 - It feels somehow vacant to have a face without eyebrows...so I made the call to the cancer support group Look Good Feel Better.
read article 



15 Ways to Cancer-Proof Your Life

(Fox News/Prevention magazine) June 7, 2013 - We're calm, we're cool, we're mostly collected...until it comes to the C-word.
read article 



Why is Nancy Brinker Still CEO of the Susan G. Komen Foundation?

(Washington Post/On Leadership blog) June 6, 2013 - The Susan G. Komen foundation announced Monday that in 2014 the breast cancer charity would be cancelling seven of its three-day walks, or half of its annual multi-day events. The organization said the cancellations were a result of economic uncertainty and competition from other charities.
read article (free registration required) 



Commentary: Cancer Patients Are Being Left Behind

(CQ Roll Call) June 5, 2013 - Just when we all thought Congress was gridlocked beyond hope, it successfully pushed through a legislative change that would improve the daily lives of millions of Americans.
read article 



CMS: No Authority to Reverse Sequestration Cuts to Cancer Care

(ASCO in Action) June 6, 2013 - The Centers for Medicare and Medicaid Services said it does not have the power to reverse or prevent the sequestration cuts to reimbursement for Part B drugs, responding to a bipartisan request for information from Congress.
read article